Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NCR101 in Interstitial Lung Disease
NCT06825169Phase 2Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of NCR101 in interstitial lung disease (ILD), sponsored by Nuwacell Biotechnologies. Primary endpoint: Adverse Event (AE) or Serious Adverse Event (SAE) at 4 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
NCR101
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06825169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825169.